Tirzepatide achieves 12% weight loss in post-bariatric patients with 100% achieving ≥5% loss at 6 months | Research

The takeaway

In 21 post-bariatric patients with weight regain or insufficient loss, tirzepatide achieved 12.0% total weight loss at 6 months (100% ≥5%, 76.5% ≥10%), with significant reductions in BMI, waist circumference, body fat, and HbA1c.

100% achieved ≥5% weight loss
Every post-bariatric patient on tirzepatide lost at least 5% of body weight, with 76.5% losing ≥10%—exceptional for this treatment-resistant population

What the researchers found

TWL: 12.0% ± 3.4% (p<0.001). ≥5% loss: 100%; ≥10%: 76.5%; ≥15%: 23.5%. Significant reductions: BMI, waist circumference, body fat %, HbA1c. Similar across sexes and surgery types. Predictors: baseline BMI nadir, weight regain, body composition, CRP.

Why it matters

Post-bariatric weight regain affects 20-30% of patients and has limited treatment options. Tirzepatide achieving 100% ≥5% weight loss in this challenging population demonstrates exceptional efficacy.

How the study worked

Retrospective analysis of 21 post-bariatric non-T2DM patients with IWL or WR treated with tirzepatide for 6 months. Body composition by BIA. Metabolic and inflammatory markers.

What this study cannot tell us

Small sample (n=21). Retrospective. No control group. 6-month follow-up. Non-diabetic patients only.

How to read the evidence

Small retrospective study without controls. Impressive results but needs confirmation in larger trials.

When this study was published

Published in 2025.

The bigger picture

This positions tirzepatide as the first highly effective pharmacological option for the growing problem of post-bariatric weight regain, with body composition data showing favorable fat-specific loss.

Questions still open

Should tirzepatide be routinely offered for post-bariatric weight regain?
Is 6-month tirzepatide sufficient or does long-term use needed?
Can the predictors identified be used to pre-select likely responders?

Common questions

Can tirzepatide help if I regain weight after bariatric surgery?

This study found tirzepatide was remarkably effective: every patient lost at least 5% of their body weight, with average loss of 12% at 6 months. The weight lost was primarily fat mass. This is significant because weight regain after bariatric surgery is a common and frustrating problem with few good treatment options.

Does the type of bariatric surgery matter?

In this study, tirzepatide worked similarly well for both sleeve gastrectomy and gastric bypass patients. Both sexes also responded equally. The main predictors of success were baseline body composition and inflammation levels rather than surgery type.

Read the original research

Tackling suboptimal clinical response after metabolic bariatric surgery: Impact of tirzepatide on weight loss and body composition.

Obesity research & clinical practice, 19(1), 63-69

View on PubMed ↗Publisher’s paper ↗

Citation

Stoll, Fabian; Kantowski, Tobias; Laaser, Jonas; Kloiber, Ulrike; Plitzko, Gabriel; Mann, Oliver; Aberle, Jens; Lautenbach, Anne. (2025). Tackling suboptimal clinical response after metabolic bariatric surgery: Impact of tirzepatide on weight loss and body composition.. Obesity research & clinical practice, 19(1), 63-69. https://doi.org/10.1016/j.orcp.2025.02.004